Overall, the combination of mineralocorticoid receptor antagonists and sodium glucose cotransporter 2 inhibitors presents a novel therapeutic strategy for managing atrial fibrillation by targeting both the underlying pathophysiological mechanisms and associated comorbidities [109,110]. The gene discussed is SLC5A2; the disease is atrial fibrillation.